Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06138990 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pharmacoscopy-guided Clinical Standard-of-care in r/r AML

Study acronym: RAPID-01
StatusUnknown
PhasePhase 2
SponsorETH Zurich
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 16, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Site details revised at 1 of 2 sites
    • Collaborators: 1 to 2
    v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Primary completion date: Mar 31, 2026 to Jun 30, 2026
    • Start date changed from estimate of Jul 1, 2024 to Sep 2, 2024
    v4
  4. Phase: Not applicable to Phase 2v3 Show 4 more changesShow less
    • Start date: Feb 1, 2024 to Jul 1, 2024
    • Enrollment target: 82 to 88
    • Primary completion date: Oct 31, 2025 to Mar 31, 2026
    • Study completion date: Dec 31, 2025 to Jun 30, 2026
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ETH Zurich
15 trials monitored
See 1 trial at risk
Leukemia
2,948 trials monitored
See 180 trials at risk
Acute Myeloid Leukemia (AML)
1,269 trials monitored
See 74 trials at risk
With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed/refractory AML.
Trial Details
NCT Number NCT06138990
Lead Sponsor ETH Zurich
Collaborators: University of Zurich, Insel Gruppe AG, University Hospital Bern
Conditions
(from sponsor)		 AML, Adult
Related terms Leukemia, Myeloid, Acute
Enrollment 88 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov